Novo Nordisk (NVO) return on equity (ROE)

Return on equity · fiscal 2025
52.8%

Novo Nordisk (NVO) earned a return on equity of 52.8% in fiscal 2025 (the year ended December 31, 2025). That is 17.6 percentage points lower than the 70.4% of fiscal 2024. Figures as of 18 Nov 2026, 00:17 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
52.8%
Change on fiscal 2024
−17.6 pts
Highest on record
78.5%fiscal 2023
Lowest on record
52.8%fiscal 2025
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Novo Nordisk return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 78.5% in fiscal 2023 and the lowest 52.8% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 70.4%.

History · 4 fiscal years

Return on equity by fiscal year

Novo Nordisk return on equity (ROE), year by year

Novo Nordisk (NVO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202552.8% 17.6 pts down
202470.4% 8.1 pts down
202378.5% 12.0 pts up
202266.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Novo Nordisk and comparable companies
CompanyReturn on equityFiscal year
Gilead Sciences GILD37.5%2025
Abbott Laboratories ABT12.5%2025
Novo Nordisk NVO52.8%2025
Pfizer PFE9.0%2025
Danaher DHR6.9%2025
Intuitive Surgical ISRG16.0%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NVO

Novo Nordisk, figure by figure

Novo Nordisk (NVO) overview: price, valuation and scorecardAll health care companies by market value

Novo Nordisk return on equity (ROE): questions and answers

What is Novo Nordisk's return on equity?

Novo Nordisk (NVO) earned a return on equity of 52.8% in fiscal 2025 (the year ended December 31, 2025). That is 17.6 percentage points lower than the 70.4% of fiscal 2024.

Is Novo Nordisk's return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 70.4%.

What are the highest and lowest return on equity figures on record for Novo Nordisk?

Across the 4 fiscal years on record (2022–2025), the highest was 78.5% in fiscal 2023 and the lowest 52.8% in fiscal 2025.

How is Novo Nordisk's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Novo Nordisk (NVO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/NVO/roe

Underlying data: Yahoo Finance.